NASDAQ:IART - Integra Lifesciences Stock Price, Forecast & News

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

Integra Lifesciences's stock split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

Integra Lifesciences Holdings Corp (NASDAQ:IART) issued its quarterly earnings results on Thursday, October, 24th. The life sciences company reported $0.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.03. The life sciences company had revenue of $379.10 million for the quarter, compared to analysts' expectations of $376.85 million. Integra Lifesciences had a net margin of 3.99% and a return on equity of 16.83%. Integra Lifesciences's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.59 earnings per share. View Integra Lifesciences' Earnings History.

Integra Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Integra Lifesciences.

Integra Lifesciences updated its fourth quarter 2019 After-Hours earnings guidance on Tuesday, January, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $395-395 million, compared to the consensus revenue estimate of $397.91 million.

11 analysts have issued 12-month price targets for Integra Lifesciences' shares. Their forecasts range from $50.00 to $75.00. On average, they expect Integra Lifesciences' stock price to reach $61.91 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for Integra Lifesciences.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Integra Lifesciences.

News articles about IART stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Integra Lifesciences earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned media coverage about the life sciences company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Integra Lifesciences.

Some companies that are related to Integra Lifesciences include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra Lifesciences investors own include Adobe (ADBE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Intel (INTC), Micron Technology (MU), Netflix (NFLX), Square (SQ), Activision Blizzard (ATVI), Celgene (CELG) and GW Pharmaceuticals PLC- (GWPH).

Integra Lifesciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (0.55%), First National Bank of Omaha (0.05%), Nisa Investment Advisors LLC (0.03%), Diversified Trust Co (0.02%), State of Alaska Department of Revenue (0.01%) and Orrstown Financial Services Inc. (0.01%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, John Mooradian, Joseph Vinhais, Keith Bradley, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Rhonda Germany Ballintyn, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.

IART stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Nisa Investment Advisors LLC, State of Alaska Department of Revenue and Huntington National Bank. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy and Richard E Caruso. View Insider Buying and Selling for Integra Lifesciences.

IART stock was bought by a variety of institutional investors in the last quarter, including Orrstown Financial Services Inc., Alpine Global Management LLC, Sciencast Management LP, First National Bank of Omaha and Diversified Trust Co. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Rhonda Germany Ballintyn. View Insider Buying and Selling for Integra Lifesciences.

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IART stock can currently be purchased for approximately $59.13.

Integra Lifesciences has a market capitalization of $5.08 billion and generates $1.47 billion in revenue each year. The life sciences company earns $60.80 million in net income (profit) each year or $2.42 on an earnings per share basis. Integra Lifesciences employs 4,500 workers across the globe.View Additional Information About Integra Lifesciences.

The official website for Integra Lifesciences is http://www.integralife.com/.

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]